Thrombolysis in myocardial infarction ( TIMI ) flow , creatine kinase MB isoenzyme ( CK-MB ) levels , acute thrombus events , efficacy and safety endpoints at Day @ , Day @ , @ months and @ year ( efficacy endpoints : death , myocardial infarction , target vessel revascularization and ischemic stroke ; safety endpoints : bleeding and thrombocytopenia ) were observed and compared between the two groups .